Epigenetic silencing of cyclooxygenase-2 affects clinical outcome in gastric cancer
The present invention discloses methods of using the methylation status of the COX-2 gene promoter region as a biomarker for a gastric cancer patient to determine a prognosis and a treatment regimen, and to monitor the progress of a treatment regimen.
John Wayne Cancer Institute (Santa Monica, CA)
Hoon, Dave S B and de Maat, Michiel, "Epigenetic silencing of cyclooxygenase-2 affects clinical outcome in gastric cancer" (2009). Technology Transfer - Patents. 38.